Related Experiment Video
Updated: Mar 29, 2026
Noninvasive Monitoring of Lesion Size in a Heterologous Mouse Model of Endometriosis
Published on: February 26, 2019
An overview of early drug development for endometriosis
Umberto Leone Roberti Maggiore1,2, Simone Ferrero1,2
1a Academic Unit of Obstetrics and Gynaecology , IRCCS AOU San Martino - IST , Genoa , Italy.
Introduction:
Endometriosis is an estrogen-dependent chronic disease of women of fertile age requiring chronic therapy. Although available drugs have good efficacy and safety profiles, some patients experience partial or no improvement of pain with conventional treatment and recurrence of symptoms after discontinuation of the therapies. For these reasons, many new compounds are currently under investigation for the treatment of endometriosis.
Areas Covered:
This review offers the reader a complete and updated overview on emerging therapies for the treatment of endometriosis. The authors describe, in detail, the laboratory and clinical studies on these therapies and highlight the potential advantages and limitations associated with the administration of these new agents.
Expert Opinion:
Gonadotropin-releasing hormone antagonists are the most intriguing emerging agents for the treatment of patients with endometriosis. It should be noted that while there are a number of drugs under investigation, a large majority of these new compounds have only been investigated in laboratory studies with more extensive research required to better elucidate their efficacy and safety profiles.
Insights
Emerging therapies, including gonadotropin-releasing hormone antagonists, show promise for endometriosis treatment. Further research is needed to confirm the efficacy and safety of these novel compounds for chronic pain management.
Area of Science:
- Reproductive Medicine
- Gynecology
- Pharmacology
Background:
- Endometriosis is a chronic, estrogen-dependent condition affecting women of reproductive age, necessitating long-term treatment.
- Current therapies offer good efficacy but may result in incomplete pain relief or symptom recurrence.
- This highlights the need for novel therapeutic strategies for endometriosis management.
Purpose of the Study:
- To provide a comprehensive review of emerging therapeutic agents for endometriosis.
- To analyze laboratory and clinical data on these novel treatments.
- To identify potential benefits and drawbacks of new endometriosis drug candidates.
Main Methods:
- Systematic review of current literature on emerging endometriosis therapies.
- Detailed examination of preclinical and clinical studies.
- Evaluation of the advantages and limitations of investigational agents.
Main Results:
- Gonadotropin-releasing hormone antagonists represent a promising class of emerging endometriosis treatments.
- Several new compounds are under investigation, with varying degrees of research completed.
- Many novel agents have primarily undergone laboratory investigation.
Conclusions:
- Gonadotropin-releasing hormone antagonists are particularly noteworthy for endometriosis management.
- Extensive research is required to fully establish the efficacy and safety profiles of most investigational drugs.
- Further clinical trials are essential to validate the therapeutic potential of new endometriosis treatments.
Related Concept Videos
01:28Preclinical Development: Overview
01:26Drug Discovery: Overview
01:21Intrauterine Drug Delivery Systems
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:11Clinical Trials: Overview